BUSINESS
Hester Biosciences plans to raise fresh funds for its proposed African animal vaccine plant
The proposed manufacturing plant expected to come up in Tanzania will manufacture vaccines against African specific bacterial and virus strains causing disease in cattle, goat and sheep.
BUSINESS
Dr Reddy's board gives nod to induct third generation leadership into the company
Dr Reddy's Laboratories board has given green signal to induct Akhil Ravi, the son-in-law of GV Prasad, Co-Chairman, and CEO - of Dr Reddy's into the company management.
BUSINESS
Wockhardt to offer its Waluj formulation facility for US FDA inspection in early 2018
The company’s formulation units at Chikalthana and Waluj in Maharashtra have been under the USFDA’s import alert since 2013, while its bulk drug plant at Ankleshwar in Gujarat was also issued an import alert.
BUSINESS
SC asks govt expert body to review banned FDC drugs before taking further action
The recommendations of the DTAB or its expert sub-committee would have to be made to the Central Government within six months, after which the government will act further if and where necessary.
BUSINESS
Homeopathy sees resurgence with govt support & more people trying alternate medicines
B Jain Pharmaceuticals, the New Delhi-based maker of homeopathic ingredients and formulations, says it sees resurgence of homeopathy in India backed by more people willing to try alternative therapies and government's own efforts to promote traditional medical practices.
BUSINESS
Antibiotics & asthma drugs help Indian pharma market to grow at 8.1% in Nov
The highest growth for any month so far in FY18, helped by improved uptake in anti-infectives, respiratory and gastrointestinal segments, despite gradual recovery from the disruption caused by GST transition, according to market research firm AIOCD-AWACS.
BUSINESS
Pharma Weekly Wrap: Pharma stocks rebound this week on buying interest
The hospital stocks remained stable despite the ongoing developments related to Delhi government cancelling license of Max Hospital Shalimar Bagh and Harayana government removing Gurugram’s Fortis Hospital from the list of empanelled hospitals.
BUSINESS
Max Hospital Shalimar Bagh licence cancelled, calls govt’s move too ‘harsh’
The Delhi government on Friday cancelled the licence of Max Hospital Shalimar Bagh on alleged “gross medical negligence” by hospital authorities in a case related to a newborn declared dead by hospital but later found alive.
BUSINESS
US FDA eases throttle on generics with highest-ever approvals in a single month
The record push in terms of approvals is part of US FDA efforts to lower prescription drug costs, an election promise of US President Donald Trump.
BUSINESS
Biocon creates new subsidiary to unlock value of its biologics business
The biologics business consists biosimilars that include monoclonal antibodies and recombinant insulins and novel biologics
BUSINESS
Pharma stocks remain subdued this week as investors book profit, Biocon stands tall
The BSE Healthcare index dropped 2.4 percent in the past week, while the BSE Sensex declined 1.3 percent
BUSINESS
US gives nod to Biocon-Mylan's biosimilar of cancer drug Herceptin, revenues expected from FY19
Ogivri is the first FDA-approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon’s joint portfolio approved in the US
BUSINESS
Govt may rethink proposal to ban contract manufacturing in draft pharma policy
A person who provided inputs to the government on preparing the Draft Pharmaceutical Policy - 2017 on condition of anonymity said that the government is aware of industry concerns over the proposal.
BUSINESS
Cipla Health to expand consumer health biz with new launches and acquisitions
The company is developing a pipeline of products in child nutrition, an area dominated by multinationals such as Abbott, GSK, Kraft Heinz and Mondelez International.
BUSINESS
GlaxoSmithKline profit rises 32% in Q2 led by recovery of inventory levels
The company posted Rs 99 crore in the year-ago quarter. Revenue for the quarter grew 5 percent to Rs 836 crore over the previous year.
BUSINESS
Govt says no changes to ceiling price methodology of scheduled drugs
“The Government has been examining the Drugs (Prices Control) Order, 2013 (DPCO) with a view to enhancing the accessibility and affordability of essential medicines at reasonable prices to the poor and needy while providing sufficient opportunity for innovation and competition to support the growth of the Pharmaceutical Industry,” said the Department of Pharmaceuticals (DoP) in a statement on Friday.
TRENDS
This week in pharma: Quiet Diwali for stocks as analysts predict challenging Q2
Here's a wrap of the key events in the pharma sector this week.
BUSINESS
US FDA issues guidelines to help generic makers to copy 32 complex drug products
US FDA has been trying to encourage competition in complex drugs through several initiatives. One of the major step is to issue new draft and revised guidance documents to provide product-specific clarity enabling generic makers to design appropriate bio-equivalence (BE) studies in support of their abbreviated new drug applications (ANDAs) filings.
BUSINESS
ICMR unveils plan to increase health research output by 30%
The apex body which oversees biomedical research in the country aims to launch at least 10 globally validated Indian traditional medicines by 2030.
BUSINESS
Amneal-Impex combine to pip Sun Pharma as the fifth-largest generic maker in US
The combined company is expected to have 2017 pro forma net revenue ranging from USD 1.75 billion to USD 1.85 billion and pro forma adjusted EBITDA of approximately USD 600 million to USD 650 million in 2017 and USD 700 million to USD 750 million in 2018, each including USD 80 million to USD 120 million of annualized cost savings within the first full year of close.
BUSINESS
Glenmark's Glenn Saldanha takes over as president of pharma lobby group IPA
Saldanha who replaces Nilesh Gupta, will be in office for next two years.
TRENDS
Indian pharma grows at mere 1% in Sept quarter, recovery from GST disruption slow
In the second quarter ended September the IPM grew 1 percent versus 14 percent in the same period previous year. Second quarter generally happens to be a good quarter for Indian drug market.
BUSINESS
MSF moves High Court against Indian patent given to Pfizer's pneumonia vaccine
In its petition MSF argued that in August 2017, the Delhi Patent Office erroneously granted a patent to Pfizer by disregarding the evidence MSF produced indicating that the pharmaceutical giant’s claim to a patent was spurious.
BUSINESS
Lupin readies for a mega specialty drug play with $1-bn war chest
Lupin on Wednesday has agreed to buy US-based Symbiomix Therapeutics for USD 150 million. The drug maker will be doing several deals in the coming quarters.
